摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-amino-4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-7-(2-methoxyethoxy)quinoline-3-carbonitrile | 1246087-19-3

中文名称
——
中文别名
——
英文名称
6-amino-4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-7-(2-methoxyethoxy)quinoline-3-carbonitrile
英文别名
6-amino-4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-7-(2-methoxyethoxy)quinoline-3-carbonitrile
6-amino-4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-7-(2-methoxyethoxy)quinoline-3-carbonitrile化学式
CAS
1246087-19-3
化学式
C25H22ClN5O3
mdl
——
分子量
475.934
InChiKey
CSKCKOHTRRWUCJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.2
  • 重原子数:
    34
  • 可旋转键数:
    9
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.16
  • 拓扑面积:
    115
  • 氢给体数:
    2
  • 氢受体数:
    8

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS
    申请人:ZHANG Hesheng
    公开号:US20100240649A1
    公开(公告)日:2010-09-23
    A compound of formula (I), a pharmaceutically acceptable salt, or hydrate thereof, and a method of preparing the same. A method of treating or preventing a physiological disorder caused by abnormal protein tyrosine kinase activity in a mammal comprising administering to said mammal a pharmaceutical composition comprising a compound of formula (I).
    化合物I的化学式,其药学上可接受的盐或水合物,以及其制备方法。一种治疗或预防哺乳动物中由异常蛋白质酪氨酸激酶活性引起的生理障碍的方法,包括向该哺乳动物施用含有化合物I的制药组合物。
  • SUBSTITUTED HETEROCYCLIC COMPOUNDS AS KINASES INHIBITORS AND METHODS OF USE THEREOF
    申请人:Zhang Dawei
    公开号:US20120101116A1
    公开(公告)日:2012-04-26
    The present invention is directed to novel quinolines and quniazolines, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof which are useful for the treatment of protein kinases mediated diseases and conditions. The compounds of this invention have a general Formula (I) wherein R 1 to R 11 and X are defined herein.
    本发明涉及新型喹啉和喹唑啉、它们的衍生物、药学上可接受的盐、溶剂和水合物,它们可用于治疗蛋白激酶介导的疾病和病症。本发明的化合物具有通式(I),其中R1至R11和X的定义如下。
  • METHODS OF PREPARING AND USING QUINAZOLINE AND QUINOLINE DERIVATIVES
    申请人:ZHANG Hesheng
    公开号:US20120225872A1
    公开(公告)日:2012-09-06
    A method of preparing a compound of formula (I), A method for treating cancer or inhibiting growth of cancer cells including administering to a patient mammal in need thereof a pharmaceutical preparation including the compound. A method of treating or preventing a physiological disorder caused by abnormal protein tyrosine kinase activity in a mammal including administering to a mammal a pharmaceutical preparation including the compound.
    一种制备化合物(I)的方法,一种治疗癌症或抑制癌细胞生长的方法,包括向需要治疗的哺乳动物患者给予包含该化合物的制药制剂。一种治疗或预防哺乳动物中由异常蛋白酪氨酸激酶活性引起的生理障碍的方法,包括向哺乳动物给予包含该化合物的制药制剂。
  • Substituted heterocyclic compounds as kinases inhibitors and methods of use thereof
    申请人:Zhang Dawei
    公开号:US08748453B2
    公开(公告)日:2014-06-10
    The present invention is directed to novel quinolines and quniazolines, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof which are useful for the treatment of protein kinases mediated diseases and conditions. The compounds of this invention have a general Formula (I) wherein R1 to R11 and X are defined herein.
    本发明涉及新型的喹啉和喹唑啉,它们的衍生物、药学上可接受的盐、溶剂合物和水合物,用于治疗蛋白激酶介导的疾病和病状。本发明的化合物具有一般式(I),其中R1至R11和X在此定义。
  • SUBSTITUTED HETEROCYCLIC COMPOUNDS AS KINASES INHIBITORS AND METHOD OF USE THEREOF
    申请人:Medolution Limited
    公开号:EP2445885A2
    公开(公告)日:2012-05-02
查看更多